Fresenius Medical Care AG (FMS)
20.76
-0.72
(-3.33%)
USD |
NYSE |
Apr 24, 16:00
20.76
0.00 (0.00%)
After-Hours: 18:33
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 12.19B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -6.00% |
| Valuation | |
| PE Ratio | 22.57 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 0.5786 |
| Price to Book Value | 0.8093 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 0.6342 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.5803 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 75.63% |
Profile
| Fresenius Medical Care is the largest dialysis company in the world, treating about 345,000 patients from over 4,100 clinics across the globe as of December 2022. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market and benefits from being the world's only fully integrated dialysis business. Services account for roughly 80% of firmwide revenue, including care coordination and ancillary operations, while products account for the other roughly 20%. Products typically enjoy a higher margin, making them a strong contributor to the bottom line. |
| URL | https://www.freseniusmedicalcare.com |
| Investor Relations URL | https://www.freseniusmedicalcare.com/en/investors/investors-overview/ |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Health Care Providers & Services |
| Equity Style | Mid Cap/Blend |
| Next Earnings Release | May. 09, 2024 (est.) |
| Last Earnings Release | Feb. 20, 2024 |
| Next Ex-Dividend Date | May. 17, 2024 |
| Last Ex-Dividend Date | May. 13, 2022 |
Ratings
Profile
| Fresenius Medical Care is the largest dialysis company in the world, treating about 345,000 patients from over 4,100 clinics across the globe as of December 2022. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market and benefits from being the world's only fully integrated dialysis business. Services account for roughly 80% of firmwide revenue, including care coordination and ancillary operations, while products account for the other roughly 20%. Products typically enjoy a higher margin, making them a strong contributor to the bottom line. |
| URL | https://www.freseniusmedicalcare.com |
| Investor Relations URL | https://www.freseniusmedicalcare.com/en/investors/investors-overview/ |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Health Care Providers & Services |
| Equity Style | Mid Cap/Blend |
| Next Earnings Release | May. 09, 2024 (est.) |
| Last Earnings Release | Feb. 20, 2024 |
| Next Ex-Dividend Date | May. 17, 2024 |
| Last Ex-Dividend Date | May. 13, 2022 |